Adenosine A 2A and dopamine D 2 receptor interaction controls fatigue resistance.

Autor: Alves ACB; Biology of Exercise Lab, Department of Health Sciences, UFSC-Federal University of Santa Catarina, Araranguá, Brazil., Santos NS; Biology of Exercise Lab, Department of Health Sciences, UFSC-Federal University of Santa Catarina, Araranguá, Brazil., Santos APT; Biology of Exercise Lab, Department of Health Sciences, UFSC-Federal University of Santa Catarina, Araranguá, Brazil., da Panatta G; Biology of Exercise Lab, Department of Health Sciences, UFSC-Federal University of Santa Catarina, Araranguá, Brazil., Speck AE; Biology of Exercise Lab, Department of Health Sciences, UFSC-Federal University of Santa Catarina, Araranguá, Brazil., Cunha RA; CNC-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.; FMUC-Faculty of Medicine, University of Coimbra, Coimbra, Portugal., Aguiar AS Jr; Biology of Exercise Lab, Department of Health Sciences, UFSC-Federal University of Santa Catarina, Araranguá, Brazil.
Jazyk: angličtina
Zdroj: Frontiers in pharmacology [Front Pharmacol] 2024 May 27; Vol. 15, pp. 1390187. Date of Electronic Publication: 2024 May 27 (Print Publication: 2024).
DOI: 10.3389/fphar.2024.1390187
Abstrakt: Introduction: Caffeine and the selective A 2A receptor antagonist SCH58261 both have ergogenic properties, effectively reducing fatigue and enhancing exercise capacity. This study investigates in male Swiss mice the interaction between adenosine A 2A receptors and dopamine D 2 receptors controlling central fatigue, with a focus on the striatum where these receptors are most abundant. Methods: We employed DPCPX and SCH58261 to antagonize A 1 and A 2A receptors, caffeine as a non-competitive antagonist for both receptors, and haloperidol as a D 2 receptor antagonist; all compounds were tested upon systemic application and caffeine and SCH58261 were also directly applied in the striatum. Behavioral assessments using the open field, grip strength, and treadmill tests allowed estimating the effect of treatments on fatigue. Results and discussion: The results suggested a complex interplay between the dopamine and adenosine systems. While systemic DPCPX had little effect on motor performance or fatigue, the application of either caffeine or SCH58261 was ergogenic, and these effects were attenuated by haloperidol. The intra-striatal administration of caffeine or SCH58261 was also ergogenic, but these effects were unaffected by haloperidol. These findings confirm a role of striatal A 2A receptors in the control of central fatigue but suggest that the D 2 receptor-mediated control of the ergogenic effects of caffeine and of A 2A receptor antagonists might occur outside the striatum. This prompts the need of additional efforts to unveil the role of different brain regions in the control of fatigue.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
(Copyright © 2024 Alves, Santos, Santos, Panatta, Speck, Cunha and Aguiar.)
Databáze: MEDLINE
Externí odkaz: